Delta Air Lines has rallied 5.4% on the week to $70.86, and the stock is up more than 6% over the past month — but options positioning and a steady climb in short interest suggest investors are not convinced the turbulence is behind them.
The clearest tension in this week's setup sits in the options market. Put/call ratio for DAL has climbed to 1.11, about one standard deviation above its 20-day mean of 1.01, placing it in noticeably more defensive territory than the recent average. That's not an extreme — the 52-week high is 1.23 — but the direction of travel matters here. In early April the PCR was running in the 0.65–0.68 range; it has since moved consistently above 1.0, and it has stayed there. Investors are buying more downside protection than upside expression. With the next earnings date confirmed for June 18, there is a concrete catalyst giving that hedging a logical home.
Short interest at 3.8% of the free float is moderate — not the kind of level that screams crowded short — but the trend is worth watching. Shorts grew roughly 18.6% over the past month, from around 20.8 million shares in late March to 24.7 million now. That's a meaningful build, even if the absolute level remains low relative to history. Borrow conditions stay relaxed: cost to borrow is 0.47%, barely changed week-on-week, and borrow availability is ample. There is no squeeze dynamic here. The short build looks like cautious positioning, not a conviction bet against the name.
The Street remains firmly in the bull camp, even after a period of mixed target movements. Most of the bullish target raises came in the days immediately following the April 8 earnings print, when Evercore ISI, UBS, TD Cowen, and Citi all lifted their numbers — UBS to $86, Evercore to $85, TD Cowen to $84. The consensus mean price target of $79.45 implies roughly 12% upside from current levels. A few analysts trimmed targets in mid-March on macro uncertainty, but none cut ratings. Valuation multiples tell a nuanced story: the P/E of 11.1x has expanded about 1.4 turns over 30 days as the stock recovered, and EV/EBITDA at 7.1x has moved similarly. Neither is stretched for an airline. The EV/EBIT factor score at the 72nd percentile suggests relative efficiency is still a talking point for bulls. EPS momentum scores, however, rank in the low teens-to-twenties percentile — meaning forward estimate revisions have been soft.
The insider picture cuts against the constructive narrative. The 90-day net flow shows net selling of approximately $161.6 million across the executive suite. COO John Laughter sold around $5.8 million in April — split across two trades near the current price level. CEO Ed Bastian sold $7 million in late February at $70.26. President Glen Hauenstein was the most active seller in early February, moving over $32 million across several transactions near $71–$75. None of these are panic sells — executives routinely monetise compensation grants — but the cluster is notable. Delta's top brass have been consistent sellers close to the current trading range, which complicates the case that the stock is deeply undervalued at this price.
Among peers, UAL gained 4.0% on the week while AAL added 6.3% — both broadly in line with DAL's move. ALGT and ALK lagged on the week despite a strong single day, ending down 2.6% and 3.2% respectively. The airline recovery trade is not lifting all carriers equally, and Delta's premium positioning gives it somewhat different demand sensitivity than its lower-cost peers.
After the April 8 Q1 print, DAL gained 3.4% on day one and 9.7% over the following week — a clean beat-and-rally setup. The prior quarter, in January, it fell 3.6% on day one and drifted 5% lower over the following week. The June 18 print is the next marker, and how management characterises summer demand trends against a still-uncertain macro backdrop will determine whether options traders' current defensiveness looks prescient or excessive.
See the live data behind this article on ORTEX.
Open DAL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
